Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Inclusion Criteria

• •Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD 30 expression
• •Patients must have absolute neutrophil count (ANC) \>= 1000/uL; neupogen (filgrastim) can be given prior to start of SGN-35 (brentuximab vedotin) and during SGN-35 treatment to achieve target ANC \>= 1000/uL
• •Patients must have platelets (Plts) \>= 50,000/uL; platelet transfusion can be given prior to the start of SGN-35 and during SGN-35 treatment to achieve a target plt \>= 50,000/uL
• •Patients must have measurable disease \> 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans
• •Patient must be either primary refractory to one frontline induction therapy or relapsed after one frontline induction therapy; patients who do not achieve complete remission after induction therapy are also eligible
• •Patients cannot have had a second line salvage treatment (chemotherapy, biologic agents, investigational drugs, or radiation) or have had an autologous or allogeneic hematopoietic stem cell transplantation; patients can have had mixed frontline therapy such as 2-4 cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) followed by 2-4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as long as the induction chemotherapy is not more than 8 cycles in total length
• •Radiation use as part of induction regimen or consolidation (within 90 days after completion of induction chemotherapy) is allowed
• •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
• •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study
• •Male subject agrees to use an acceptable method of contraception for the duration of the study
• •Life expectancy of greater than 3 months
• •Karnofsky performance status of \> 60%
• •ANC \>= 1000/uL
• •Plts \>= 50,000/uL
• •Total bilirubin within 1.5 x of the upper limit of normal (ULN) institutional limits, patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
• •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 2.5 X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)
• •Calculated creatinine clearance \>30 ml/min (unless demonstrated Hodgkin lymphoma involvement of the kidney)
• •ELIGIBILITY FOR 2.4 MG/KG DOSING IN THE NEW COHORT: